Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

383 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Initial treatment patterns over time for anaplastic oligodendroglial tumors.
Panageas KS, Iwamoto FM, Cloughesy TF, Aldape KD, Rivera AL, Eichler AF, Louis DN, Paleologos NA, Fisher BJ, Ashby LS, Cairncross JG, Roldán Urgoiti GB, Wen PY, Ligon KL, Schiff D, Robins HI, Rocque BG, Chamberlain MC, Mason WP, Weaver SA, Green RM, Kamar FG, Abrey LE, Deangelis LM, Jhanwar SC, Rosenblum MK, Lassman AB. Panageas KS, et al. Among authors: chamberlain mc. Neuro Oncol. 2012 Jun;14(6):761-7. doi: 10.1093/neuonc/nos065. Epub 2012 May 31. Neuro Oncol. 2012. PMID: 22661585 Free PMC article.
International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors.
Lassman AB, Iwamoto FM, Cloughesy TF, Aldape KD, Rivera AL, Eichler AF, Louis DN, Paleologos NA, Fisher BJ, Ashby LS, Cairncross JG, Roldán GB, Wen PY, Ligon KL, Schiff D, Robins HI, Rocque BG, Chamberlain MC, Mason WP, Weaver SA, Green RM, Kamar FG, Abrey LE, DeAngelis LM, Jhanwar SC, Rosenblum MK, Panageas KS. Lassman AB, et al. Among authors: chamberlain mc. Neuro Oncol. 2011 Jun;13(6):649-59. doi: 10.1093/neuonc/nor040. Neuro Oncol. 2011. PMID: 21636710 Free PMC article.
Recursive partitioning analysis of prognostic variables in newly diagnosed anaplastic oligodendroglial tumors.
Panageas KS, Reiner AS, Iwamoto FM, Cloughesy TF, Aldape KD, Rivera AL, Eichler AF, Louis DN, Paleologos NA, Fisher BJ, Ashby LS, Cairncross JG, Urgoiti GB, Wen PY, Ligon KL, Schiff D, Robins HI, Rocque BG, Chamberlain MC, Mason WP, Weaver SA, Green RM, Kamar FG, Abrey LE, DeAngelis LM, Jhanwar SC, Rosenblum MK, Lassman AB. Panageas KS, et al. Among authors: chamberlain mc. Neuro Oncol. 2014 Nov;16(11):1541-6. doi: 10.1093/neuonc/nou083. Epub 2014 Jul 4. Neuro Oncol. 2014. PMID: 24997140 Free PMC article.
Seizure control as a new metric in assessing efficacy of tumor treatment in low-grade glioma trials.
Avila EK, Chamberlain M, Schiff D, Reijneveld JC, Armstrong TS, Ruda R, Wen PY, Weller M, Koekkoek JA, Mittal S, Arakawa Y, Choucair A, Gonzalez-Martinez J, MacDonald DR, Nishikawa R, Shah A, Vecht CJ, Warren P, van den Bent MJ, DeAngelis LM. Avila EK, et al. Neuro Oncol. 2017 Jan;19(1):12-21. doi: 10.1093/neuonc/now190. Epub 2016 Sep 20. Neuro Oncol. 2017. PMID: 27651472 Free PMC article. Review.
The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteria.
Nayak L, DeAngelis LM, Brandes AA, Peereboom DM, Galanis E, Lin NU, Soffietti R, Macdonald DR, Chamberlain M, Perry J, Jaeckle K, Mehta M, Stupp R, Muzikansky A, Pentsova E, Cloughesy T, Iwamoto FM, Tonn JC, Vogelbaum MA, Wen PY, van den Bent MJ, Reardon DA. Nayak L, et al. Neuro Oncol. 2017 May 1;19(5):625-635. doi: 10.1093/neuonc/nox029. Neuro Oncol. 2017. PMID: 28453751 Free PMC article. Review.
Clinical trial end points for high-grade glioma: the evolving landscape.
Reardon DA, Galanis E, DeGroot JF, Cloughesy TF, Wefel JS, Lamborn KR, Lassman AB, Gilbert MR, Sampson JH, Wick W, Chamberlain MC, Macdonald DR, Mehta MP, Vogelbaum MA, Chang SM, Van den Bent MJ, Wen PY. Reardon DA, et al. Among authors: chamberlain mc. Neuro Oncol. 2011 Mar;13(3):353-61. doi: 10.1093/neuonc/noq203. Epub 2011 Feb 9. Neuro Oncol. 2011. PMID: 21310734 Free PMC article. Review.
A phase II study of bevacizumab and erlotinib after radiation and temozolomide in MGMT unmethylated GBM patients.
Raizer JJ, Giglio P, Hu J, Groves M, Merrell R, Conrad C, Phuphanich S, Puduvalli VK, Loghin M, Paleologos N, Yuan Y, Liu D, Rademaker A, Yung WK, Vaillant B, Rudnick J, Chamberlain M, Vick N, Grimm S, Tremont-Lukats IW, De Groot J, Aldape K, Gilbert MR; Brain Tumor Trials Collaborative. Raizer JJ, et al. J Neurooncol. 2016 Jan;126(1):185-192. doi: 10.1007/s11060-015-1958-z. J Neurooncol. 2016. PMID: 26476729 Free PMC article. Clinical Trial.
383 results